Accepted Manuscripts
Back to the articles list |
Back to browse issues page
Heba Rady Salem 
, Gergess Hanna , Mohammed Hassan , Safaa El-kotb , Samar Rashad , Rania Ibrahim Yassien , Mahmoud Selim , Ghada Samir Amer
, Gergess Hanna , Mohammed Hassan , Safaa El-kotb , Samar Rashad , Rania Ibrahim Yassien , Mahmoud Selim , Ghada Samir Amer
Abstract: (183 Views)
Background: Improper glycaemic control is associated with diabetic cognitive dysfunction. Several studies confirmed the neuroprotective effect of metformin and insulin. This study aimed to investigate the effect of metformin and/or insulin therapy on neurocognitive functions in type 2 diabetes mellitus (T2DM) rat model.
Methods: Fifty adults male Wistar rats were used in this study. They had free access to water and normal chow diet. After acclimatization period, 10 rats were kept on normal chow diet and considered as control group. T2DM was induced in the other 40 rats by high fat diet and low dose streptozotocin method. Then, diabetic rats were randomly allocated into 4 equal groups: Non-treated diabetic group; Metformin-treated diabetic group, they were treated with metformin (250 mg/kg/day) for 6 weeks; Insulin-treated diabetic group, they were treated with NPH insulin (40 U/kg) for 6 weeks; and Metformin and insulin-treated diabetic group. Neurocognitive functions were assessed by footprint assay, Y- maze, open field test and Morris water maze. Glycaemic profile, serum levels of amyloid A, interleukin-18 and nuclear factor-kappa B were analysed. Brain malondialdehyde and total antioxidant capacity were measured. Histopathological examination of frontal lobe was performed.
Results: Treatment with metformin and/or insulin significantly improved the impaired neurocognitive dysfunction, brain oxidative stress, changes in biochemical parameters, and the associated histopathological changes in the frontal cortex of diabetic rats. The combined therapy showed better effect than either monotherapy alone.
Conclusion: Metformin and insulin therapy may be valuable for prevention of neurocognitive dysfunction in T2DM.
Methods: Fifty adults male Wistar rats were used in this study. They had free access to water and normal chow diet. After acclimatization period, 10 rats were kept on normal chow diet and considered as control group. T2DM was induced in the other 40 rats by high fat diet and low dose streptozotocin method. Then, diabetic rats were randomly allocated into 4 equal groups: Non-treated diabetic group; Metformin-treated diabetic group, they were treated with metformin (250 mg/kg/day) for 6 weeks; Insulin-treated diabetic group, they were treated with NPH insulin (40 U/kg) for 6 weeks; and Metformin and insulin-treated diabetic group. Neurocognitive functions were assessed by footprint assay, Y- maze, open field test and Morris water maze. Glycaemic profile, serum levels of amyloid A, interleukin-18 and nuclear factor-kappa B were analysed. Brain malondialdehyde and total antioxidant capacity were measured. Histopathological examination of frontal lobe was performed.
Results: Treatment with metformin and/or insulin significantly improved the impaired neurocognitive dysfunction, brain oxidative stress, changes in biochemical parameters, and the associated histopathological changes in the frontal cortex of diabetic rats. The combined therapy showed better effect than either monotherapy alone.
Conclusion: Metformin and insulin therapy may be valuable for prevention of neurocognitive dysfunction in T2DM.
Type of Manuscript: Experimental research article |
Subject:
Neurophysiology/Pharmacology
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
